Experimental herpes vaccine passes first safety check in small trial
NCT ID NCT01915212
First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 5 times
Summary
This early-stage trial tested whether a new herpes vaccine called HSV529 is safe for people. Researchers gave the vaccine or a placebo to 69 healthy adults aged 18 to 40, some of whom had herpes and some who did not. Participants received three shots over six months and were monitored for side effects and immune responses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HSV529 vaccine
- What this could lead to
- If successful, this could pave the way for a vaccine to prevent genital herpes infections.
- What could go wrong
- This is an early Phase 1 safety trial with only 69 participants, so it cannot yet prove the vaccine works. The vaccine may not generate strong enough immunity or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults